Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain

NCT ID: NCT03337607

Last Updated: 2025-01-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-13
• Study Completion Date: 2019-08-01

Brief Summary

This study tests the hypothesis that radial extracorporeal shock wave therapy (rESWT) in combination with the non-steroidal anti-inflammatory drug Celecoxib and the antispasmodic drug Eperisone (hereafter, "C-E drug therapy") is statistically significantly more effective than either rESWT or C-E drug therapy alone in the treatment of chronic non-specific low back pain.

Detailed Description

Non-specific low back pain is defined as low back pain not attributable to a recognizable, known specific pathology (e.g., infection, tumour, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome). It is second only to the common cold as the most common affliction of mankind and is among the leading complaints bringing patients to physicians' offices. The reported point prevalence of non-specific low back pain is as high as 33 percent, its one-year prevalence as high as 73 percent and its lifetime prevalence exceeds 70% in most industrialized countries, with an annual incidence of 15% to 20% in the United States of America. In physically active adults not seeking medical attention, the annual incidence of clinically significant non-specific low back pain with functional impairment is approximately 10 to 15 percent. In China, non-specific low back pain has become one of the leading causes of disability-adjusted life-years (DALYs) in 2010. Some authors reported the prevalence of non-specific low back pain as 41% in Chinese adolescents.

Management for patients with non-specific low back pain is challenged by the problems that most back pain has no recognizable cause (>85%), an underlying systemic disease is rare, and most episodes of back pain are unpreventable.

Acute non-specific low back pain (lasting three to six weeks) usually resolves in several weeks, although recurrences are common and low-grade symptoms are often present years after an initial episode. Risk factors for the development of disabling chronic or persistent non-specific low back pain (variously defined as lasting more than three months or more than six months) include preexisting psychological distress, disputed compensation issues, other types of chronic pain, and job dissatisfaction.

The goals of management for patients with non-specific low back pain are to decrease the pain, restore mobility, hasten recovery so the patient can resume normal daily activities as soon as possible, (iv) prevent development of a chronic recurrent condition, and restore and preserve physical and financial independence and comfort.

Unfortunately, few if any treatments have been proven effective for non-specific low back pain in meta-analyses, including limited bed rest, physical activity and exercise, back schools, traction, massage, chiropractic, radiofrequency denervation, paracetamol, opioids and, ultimately, surgery (in cases of cauda equina syndrome, infections, tumors and fractures compressing the spinal cord, mechanical instability of the back, and, perhaps, intractable pain with a positive straight-leg-raising test and no response to conservative therapy). Earlier studies demonstrated that muscle relaxants are effective in the management of non-specific low back pain, but the adverse effects require that they be used with caution. Accordingly, the aforementioned guideline by the American College of Physicians is only based on low- and moderate-quality evidence.

Recently extracorporeal shock wave therapy (ESWT) was introduced into the management of non-specific low back pain. The use of extracorporeal shock waves (ESWs) in medicine was first reported over 30 years ago as a treatment for kidney stones, and is commonly referred to as extracorporeal shock wave lithotripsy (ESWL). Extracorporeal shock waves are also used as a treatment for various musculoskeletal conditions such as calcifying tendinopathy of the shoulder, epicondylitis, Achilles tendinopathy and plantar fasciitis, and is commonly referred to as 'extracorporeal shock wave therapy', or 'ESWT' to differentiate from ESWL. ESWT is effective and safe, and for the aforementioned conditions randomized controlled trials (RCTs) on ESWT were the predominant type of RCT listed in the PEDro database and/or obtained the highest PEDro scores among all investigated treatment modalities.

There are three different types of ESWs used in ESWT for musculoskeletal conditions, focused, defocused and radial, and several modes of operation of focused, defocused and radial extracorporeal shock wave generators. Focused, defocused and radial ESWs are single acoustic impulses with an initial high positive peak pressure between 10 and 100 megapascals (MPa) reached in less than one microsecond (µs). The positive pressure amplitude is followed by a low tensile amplitude of a few microseconds duration that can generate cavitation. They are further characterized by a short life cycle of approximately 10-20 µs and a broad frequency spectrum. Focused ESWs differ from radial ESWs in the penetration depth into the tissue, some physical characteristics, and the technique for generating them. However, without going into detail, there is no scientific evidence in favor of either radial ESWT (rESWT) or focused ESWT (fESWT) with respect to treatment outcome, and no scientific evidence that a certain fESWT technology is superior to the other technologies.

Several molecular and cellular mechanisms were reported on how ESWs might mediate their pain-relieving action. Specifically, exposure of the distal femur of rabbits to focused ESWs decreased the amount of Substance P (SP) in the periosteum and diminished the number of neurons immunoreactive for substance P in dorsal root ganglia L5. Furthermore, application of shock waves to rat skin decreased calcitonin gene-related peptide (CGRP) immunoreactivity in dorsal root ganglion neurons. Substance P is concentrated in unmyelinated C-fibers (responsible for throbbing, chronic pain) and a subpopulation of slowly conducting, lightly myelinated A-delta nerve fibers, and is released at central and peripheral terminals of sensory nociceptive neurons after stimulation. CGRP is a marker of sensory neurons typically involved with pain perception and was immunohistochemically co-localized with substance P in capsaicin-sensitive axons. Activation of peripheral small diameter sensory neurons by local depolarization, axonal reflexes, or dorsal root reflexes releases substance P and CGRP. Both substances then act on target cells in the periphery such as mast cells, immune cells and vascular smooth muscle cells, thus producing inflammation. This phenomenon is called neurogenic inflammation, and is an inflammatory symptom that results from the release of substances from primary sensory nerve terminals. Evidence has emerged that chronic inflammation contributes to the etiology of pain in insertion tendinopathies such as tennis elbow and chronic plantar fasciitis. Furthermore, it was found that SP (as well as interleukin 1 alpha and transforming growth factor beta-1) are involved in the pathogenesis of tennis elbow, without apparent infiltration of inflammatory cells. Moreover, depletion of substance P was repeatedly shown to reduce experimentally induced inflammation of paws and joints in laboratory animals. It is therefore reasonable to hypothesize that reduction of SP and CGRP in the target tissue in conjunction with reduced synthesis of this molecule in dorsal root ganglia cells plays an important role in ESWT-mediated long-term analgesia in the treatment of musculoskeletal conditions.

With respect to non-specific low back pain it is important to note that in rats, the presence of SP and CGRP immunoreactive nerve fibers was demonstrated in the lumber facet joints. Furthermore, SP immunoreactive fibers were found more extensively in lumbar intervertebral discs from patients with discogenic low back pain than in normal control discs, together with the formation of a zone of vascularized granulation tissue from the nucleus pulposus to the outer part of the annulus fibrosus along the edges of the fissures. These findings suggested that the zone of granulation tissue with extensive innervation along the tears in the posterior part of the painful disc may be responsible for causing the pain of discography and of discogenic low back pain. Accordingly, ESWT could be of great significance in the treatment of persistent non-specific low back pain.

The studies on ESWT for non-specific low back pain performed so far have only established very limited evidence of efficacy and safety of ESWT for non-specific low back pain. This is due to low sample size, lack of power analyses, lack of reporting critical information such as the follow-up interval, and the fact that only one RCT on this indication was performed so far.

Accordingly, further research is needed to support the use of ESWT for non-specific low back pain. Taking into account the well-known molecular and cellular mechanisms of action of ESWT in pain relief (outlined in detail above), the proven efficacy and safety of rESWT for treating musculoskeletal conditions, and the fact that a ceratin rESWT device provided by Electro Medical Systems (Nyon, Switzerland) has become by far the best investigated ESWT technology in the field of Evidence Based Medicine, it is reasonable to hypothesize that treatment of non-specific low back pain with rESWT is not only effective and safe but will get widespread acceptance and clinical use as soon as effectiveness and safety will be demonstrated in a randomized controlled trial. This is the purpose of the proposed project.

The standard therapy of chronic non-specific low back pain at the Department of Pain Medicine at the First Affiliated Hospital of Zhejiang University consists of the non-steroidal anti-inflammatory drug Celecoxib and the antispasmodic drug Eperisone (hereafter, "C-E drug therapy"). Considering the established evidence of superiority of combination therapies of rESWT and other treatment modalities (such as the combination of rESWT and plantar fascia-specific stretching in case of chronic plantar fasciitis and the combination of rESWT and eccentric loading in case of chronic midportion Achilles tendinopathy) the proposed study will specifically test the hypothesis that rESWT in combination with C-E drug therapy is statistically significantly more effective than either rESWT or C-E drug therapy alone in the treatment of chronic non-specific low back pain.

Conditions

Low Back Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

rESWT plus C-E drugs

Patients will receive rESWT, Celecoxib and Eperisone

Group Type: ACTIVE_COMPARATOR

rESWT

Intervention Type: DEVICE

rESWT will be performed as follows:

• Four rESWT sessions
• One rESWT session per week
• 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.
• rESWs applied at 15 Hz
• Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.
• No application of local anaesthetics

Celecoxib

Intervention Type: DRUG

1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks

Eperisone

Intervention Type: DRUG

3 x 50 mg per day for four weeks

rESWT alone

Patients will receive rESWT

Group Type: ACTIVE_COMPARATOR

rESWT

Intervention Type: DEVICE

rESWT will be performed as follows:

• Four rESWT sessions
• One rESWT session per week
• 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.
• rESWs applied at 15 Hz
• Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.
• No application of local anaesthetics

C-E drugs alone

Patients will receive Celecoxib and Eperisone

Group Type: ACTIVE_COMPARATOR

Celecoxib

Intervention Type: DRUG

1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks

Eperisone

Intervention Type: DRUG

3 x 50 mg per day for four weeks

Interventions

rESWT

rESWT will be performed as follows:

• Four rESWT sessions
• One rESWT session per week
• 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.
• rESWs applied at 15 Hz
• Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.
• No application of local anaesthetics

Intervention Type: DEVICE

Celecoxib

1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks

Intervention Type: DRUG

Eperisone

3 x 50 mg per day for four weeks

Intervention Type: DRUG

Other Intervention Names

non-steroidal anti-inflammatory drug; antispasmodic drug

Eligibility Criteria

Inclusion Criteria

• Adults (both male and female) with non-specific low back pain for more than three months.
• Age range: between 18 and 80 years.
• Willingness of the patient to participate in the study, and written informed consent signed and personally dated by the patient.
• Chronic non-specific low back pain clinically diagnosed as repeated lumbar sourness and swelling pain or a chronic progressive process, accompanied by (i) X-ray examination to exclude lumbar vertebrate fractures, spondylolysis, spondylolisthesis and severe osteoporosis, and/or (ii) MRI with normal signal or low nucleus pulposus signal.
• No contraindications for rESWT.

Exclusion Criteria

• Children and teenagers below the age of 18.
• Elderly aged >80 years old
• No willingness of the patient to participate in the study, and/or written informed consent not signed and not personally dated by the patient.
• Previous spinal fracture or spinal surgery.
• Protrusion of a lumbar intervertebral disk, ankylosing spondylitis, scoliosis, lumbar spondylolisthesis and lumbar spondylolysis.
• Systemic disorders and psychiatric disorders.
• Contraindications of C-E drug treatment (treatment of patients allergy to celecoxib, eperisone or sulfonamides, patients with gastrointestinal bleeding or bleeding history, patients with renal dysfunction, patients with severe heart failure, and lactating women).
• Contraindications of rESWT ( pregnant patients, patients with blood-clotting disorders [including local thrombosis], patients treated with oral anticoagulants, patients with local tumors, patients with local bacterial and/or viral infections [including lumbar vertebral tuberculosis], and patients treated with local corticosteroid applications in the time period of six weeks before the first rESWT session [if applicable]).
• Participation in any other clinical trial in the time period of 12 weeks before potential inclusion in the proposed study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zyiying Feng, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Pain Medicine, First Affiliated Hospital of Zhejiang University, Hangzhou, China

Locations

Department of Pain Medicine, First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

Countries

China

References

Guo X, Li L, Yan Z, Li Y, Peng Z, Yang Y, Zhang Y, Schmitz C, Feng Z. Efficacy and safety of treating chronic nonspecific low back pain with radial extracorporeal shock wave therapy (rESWT), rESWT combined with celecoxib and eperisone (C + E) or C + E alone: a prospective, randomized trial. J Orthop Surg Res. 2021 Dec 4;16(1):705. doi: 10.1186/s13018-021-02848-x.

Reference Type: DERIVED

PMID: 34863239 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

FengDolorClastLowBackPain

Identifier Type: -

Identifier Source: org_study_id